Clinical Trial Detail

NCT ID	NCT04000529
Title	Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	colorectal cancer gastrointestinal stromal tumor esophagus squamous cell carcinoma lung non-small cell carcinoma head and neck squamous cell carcinoma
Therapies	Spartalizumab + TNO155 Ribociclib + TNO155
Age Groups:	senior adult